Moderna is in the process of integrating generative AI responsibly and seamlessly into its operations and capitalizing on next-generation AI innovation.
Enables Bristol Myers Squibb to expand its manufacturing capacity, meeting the growing demand for its range of cell therapies through Cellares’ platform.
New joint venture aims to cover the entire drug discovery process, spanning early drug discovery research through the inception of drug discovery startups.
The partnership leverages Variant Bio’s genomic discovery capabilities and VB-Inference platform as well as Evotec’s expertise in antifibrotic drug discovery.